Literature DB >> 2102083

Postprandial lipemia, fenofibrate and coronary artery disease.

H S Simpson1, C M Williamson, T Olivecrona, S Pringle, J Maclean, A R Lorimer, F Bonnefous, Y Bogaievsky, C J Packard, J Shepherd.   

Abstract

This report describes the response of patients with severe coronary artery disease to a dynamic fat load test and monitors the change induced by fenofibrate therapy. The presence of disease was associated with prolonged and exaggerated hypertriglyceridemia following the meal and with lower basal HDL cholesterol and HDL subfraction masses. A further indicator of risk was the persistence of increased amounts of retinyl palmitate in the plasma of severely affected individuals 24 h after its ingestion with the meal. These observations are consistent with the proposal that the clearance of chylomicrons and their remnants is impaired in coronary atherosclerosis. Fenofibrate reduced alimentary lipemia following the fat load in both normo- and hypercholesterolemic subjects. This was associated with a 10% rise in plasma HDL cholesterol levels. The improvement in chylomicron catabolism probably derived from a 37% increase (P less than 0.001) in lipoprotein lipase activity induced by fenofibrate. Hepatic lipase on the other had was only slightly affected by treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2102083     DOI: 10.1016/0021-9150(90)90111-u

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  18 in total

Review 1.  Postprandial lipemia and coronary risk.

Authors:  W Patsch; H Esterbauer; B Föger; J R Patsch
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 2.  Bioactive peptides and proteins from foods: indication for health effects.

Authors:  Niels Peter Möller; Katharina Elisabeth Scholz-Ahrens; Nils Roos; Jürgen Schrezenmeir
Journal:  Eur J Nutr       Date:  2008-05-27       Impact factor: 5.614

3.  Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.

Authors:  T Ebara; R Ramakrishnan; G Steiner; N S Shachter
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

4.  Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia.

Authors:  B Föger; H Drexel; T Hopferwieser; G Miesenböck; A Ritsch; M Lechleitner; G Tröbinger; J R Patsch
Journal:  Clin Investig       Date:  1994-03

5.  Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction.

Authors:  Marius Carstensen; Claus Thomsen; Ole Gotzsche; Jens Juul Holst; Jürgen Schrezenmeir; Kjeld Hermansen
Journal:  Rev Diabet Stud       Date:  2005-02-10

Review 6.  Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  B H Wolffenbuttel; T W van Haeften
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

7.  Metabolism of triglyceride-rich lipoproteins during alimentary lipemia.

Authors:  F Karpe; G Steiner; T Olivecrona; L A Carlson; A Hamsten
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus.

Authors:  Gissette Reyes-Soffer; Steve Holleran; Wahida Karmally; Colleen I Ngai; Niem-Tzu Chen; Margarita Torres; Rajasekhar Ramakrishnan; William S Blaner; Lars Berglund; Henry N Ginsberg; Catherine Tuck
Journal:  J Lipid Res       Date:  2009-05-08       Impact factor: 5.922

9.  Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM.

Authors:  J Jeppesen; M Y Zhou; Y D Chen; G M Reaven
Journal:  Diabetologia       Date:  1994-08       Impact factor: 10.122

Review 10.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors:  M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.